Anjali Srivastava: WHO has launched a public consultation on the TPP for paediatric formulations
Anjali Srivastava, global health consultant for the WHO Cancer team and Board member of the Breast Cancer in Young Women’s Foundation, shared a post on LinkedIn:
“Help Shape the Future of Paediatric Cancer Treatments.
Join the public consultation and share your insights.
Deadline for feedback: 31 March, 2025 at 23:59 CET
The availability of child-friendly cancer treatments remains a critical gap in global health. To address this, the World Health Organization (WHO) has launched a public consultation on the Target Product Profile (TPP) for paediatric formulations of key oncology medicines, including:
- Cyclophosphamide
- Etoposide
- Mercaptopurine
- Methotrexate
- Procarbazine
- Temozolomide
WHO is calling on healthcare professionals, researchers, industry experts, and advocates to provide input and ensure these medicines meet the needs of children worldwide.
Why is this important?
Many essential cancer treatments were designed for adults, leaving children without optimal formulations. By defining clear product expectations, this TPP aims to guide the development of better, age-appropriate medicines that improve safety, efficacy, and access for paediatric patients.
Together, we can close the treatment gap and ensure every child receives the medicines they need, in the right formulation, at the right time.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023